Iron Panel Complete Guide: Interpreting Every Marker from Serum Iron to Soluble Transferrin Receptor

A comprehensive guide to interpreting a full iron panel in Australia — serum iron, ferritin, transferrin saturation, TIBC, UIBC, and soluble transferrin receptor. Covers optimal vs lab reference ranges, iron deficiency without anaemia, haemochromatosis, and HFE gene screening.

Disclaimer: This article is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any health-related decisions based on blood test results, including iron supplementation or genetic testing.

A full iron panel is one of the most information-dense investigations available in routine Australian pathology — and one of the most frequently misread. The individual markers are often reported with wide reference ranges derived from population statistics, and a result returned as "normal" can conceal states that meaningfully affect energy metabolism, cognitive function, immune competence, and long-term organ health.

The problem is compounded by the fact that the markers interact. Serum iron in isolation is nearly useless. Ferritin without transferrin saturation misses haemochromatosis in its early stages. And the soluble transferrin receptor — the most sensitive marker for true tissue iron deficiency — is rarely included on the standard panel at all, leaving the most clinically important pattern invisible to most practitioners.

This guide covers every component of a complete iron panel: what each marker measures, how to interpret it in context, where the reference ranges underperform, and how to read the panel as an integrated system rather than a list of individual numbers.

What a Full Iron Panel Includes

A standard "iron studies" request in Australian pathology typically returns five markers. A full panel extends to seven. Understanding what each measures is the foundation for interpretation.

| Marker | What It Measures | Australian Unit | |---|---|---| | Serum iron | Iron currently in circulation, bound to transferrin | µmol/L | | Ferritin | Iron storage protein — reflects total body iron stores | µg/L | | Transferrin | The transport protein that carries iron through the bloodstream | g/L | | TIBC | Total iron binding capacity — maximum transferrin can carry | µmol/L | | UIBC | Unsaturated iron binding capacity — spare capacity on transferrin | µmol/L | | Transferrin saturation | Percentage of transferrin currently loaded with iron | % | | Soluble transferrin receptor (sTfR) | Tissue iron demand signal — rises when cells are iron-starved | mg/L or nmol/L |

The first five are available with any "iron studies" request from a GP or via private pathology. Transferrin saturation is calculated (serum iron ÷ TIBC × 100) and is typically reported automatically. UIBC is similarly calculated (TIBC − serum iron). Soluble transferrin receptor must be specifically requested — it is not included in a standard iron studies panel and attracts an additional cost.

Always order iron studies in a fasting state. An overnight fast of 8–12 hours is required for accurate serum iron and transferrin saturation results. Dietary iron absorbed in the hours before a blood draw can substantially elevate serum iron and TSAT, producing a falsely reassuring picture in someone who is genuinely deficient. Morning collection is standard practice.

A concurrent full blood count (FBC) is strongly recommended — haemoglobin, MCV, and MCH provide essential context for understanding whether iron deficiency has progressed to anaemia, and which form of anaemia is present.

Serum Iron: Informative Only in Context

Serum iron measures the iron currently circulating in plasma, bound to transferrin. It is the most volatile marker on the panel — fluctuating substantially with time of day, recent dietary intake, illness, menstrual cycle phase, and even psychological stress.

Reference ranges in Australian pathology:

| Category | Range (µmol/L) | |---|---| | Low | <10 µmol/L | | Normal | 10–30 µmol/L | | Elevated | >30 µmol/L |

Functional optimal: 14–25 µmol/L in a fasted morning sample.

The critical caveat is that serum iron is only informative alongside TIBC and ferritin. A low serum iron could reflect genuine iron deficiency, anaemia of chronic disease (where iron is sequestered by inflammation), or simple diurnal variation at afternoon collection. A high serum iron could reflect haemochromatosis, recent supplementation, or haemolysis. The number means little without the rest of the panel.

Ferritin: The Stores Marker — and Its Limitations

Ferritin is the primary marker of iron stores — reflecting iron held in hepatocytes, macrophages, and bone marrow. It is the most clinically important single marker for detecting iron deficiency in its early stages, before haemoglobin has fallen.

For a detailed breakdown of ferritin interpretation, optimal ranges by sex and age, the symptomatic zone of 20–50 µg/L, and the causes of both low and high ferritin, see our detailed ferritin guide.

The critical limitation of ferritin as a standalone marker is that it is an acute phase reactant. In the presence of systemic inflammation — infection, autoimmune disease, metabolic syndrome, non-alcoholic fatty liver disease — ferritin is upregulated independently of iron status. This means elevated ferritin does not always indicate iron excess, and in the context of chronic inflammation, even a "normal" ferritin can mask co-existing iron deficiency.

Functional optimal ranges vs Australian lab reference ranges:

| Population | Lab Reference Range | Functional Optimal | |---|---|---| | Adult men | 30–500 µg/L | 80–200 µg/L | | Premenopausal women | 12–200 µg/L | 50–150 µg/L | | Postmenopausal women | 30–300 µg/L | 70–180 µg/L |

The gap between the lab lower bound for women (as low as 12 µg/L at some laboratories) and the functional optimal floor of 50 µg/L represents the most common missed diagnosis in Australian primary care: a woman with ferritin of 18 µg/L returned as "within range" while experiencing fatigue, hair loss, poor exercise recovery, and impaired thyroid hormone conversion. The lab reference range captures statistical normality in a population with widespread subclinical deficiency — not functional sufficiency.

Transferrin and TIBC: Reading Iron Demand

Transferrin is the glycoprotein that transports iron through the bloodstream, delivering it to cells via transferrin receptors. The body upregulates transferrin production when iron is scarce — a compensatory response to maximise capture of available circulating iron. TIBC (total iron binding capacity) measures the total carrying capacity of all transferrin in the blood — it is effectively a calculated expression of transferrin concentration in µmol/L terms.

Reference ranges:

| Marker | Low | Normal | Elevated | |---|---|---|---| | Transferrin | <2.0 g/L | 2.0–3.6 g/L | >3.6 g/L | | TIBC | <45 µmol/L | 45–72 µmol/L | >72 µmol/L |

Elevated transferrin/TIBC signals iron deficiency — the body is producing more transport protein to capture what little circulating iron exists. This is one of the most reliable diagnostic patterns in iron metabolism.

Suppressed transferrin/TIBC is seen in inflammation (acute phase suppression), liver disease (impaired synthesis), malnutrition, and iron overload (when transferrin synthesis is downregulated because stores are saturated).

The interplay between transferrin and ferritin is particularly important in distinguishing true iron deficiency from anaemia of chronic disease. In true deficiency, ferritin is low and transferrin is high. In anaemia of chronic disease, ferritin is normal or elevated and transferrin is suppressed — because the inflammatory state simultaneously raises ferritin and lowers transferrin, inverting the expected pattern.

UIBC: The Spare Capacity Signal

UIBC (unsaturated iron binding capacity) is the difference between TIBC and serum iron — it represents the spare carrying capacity remaining on transferrin that is not yet occupied by iron.

Reference range: Approximately 25–55 µmol/L, though this varies between laboratories.

Elevated UIBC (lots of spare capacity) indicates iron deficiency — most of transferrin's binding sites are unoccupied because there is insufficient iron to load them.

Low UIBC (minimal spare capacity) indicates iron loading — either iron overload states such as haemochromatosis, or states where transferrin itself is suppressed (inflammation, liver disease).

UIBC is redundant with TIBC and transferrin saturation for most clinical purposes, but it is occasionally useful when transferrin and serum iron are discordant, as it provides a third independent angle on the same physiological question.

Transferrin Saturation: The Most Actionable Marker

Transferrin saturation (TSAT) is calculated as (serum iron ÷ TIBC) × 100. It represents the percentage of transferrin's carrying capacity that is currently occupied by iron — a direct measure of iron delivery to tissues.

TSAT is the key marker for two opposite clinical scenarios: iron deficiency (very low TSAT) and iron overload/haemochromatosis (very high TSAT). It is more diagnostically useful than serum iron alone because it normalises iron levels to the available transport capacity.

Transferrin saturation interpretation:

| Transferrin Saturation | Interpretation | |---|---| | <16% | Iron deficiency — insufficient iron to load transferrin | | 16–20% | Suboptimal — functional deficiency possible, especially with low ferritin | | 20–35% | Functional optimal — adequate iron delivery to tissues | | 35–45% | Upper-normal — monitor; context-dependent | | >45% | Elevated — warrants haemochromatosis investigation on a fasting sample | | >60% | Strongly elevated — high clinical suspicion for haemochromatosis or significant iron overload |

TSAT below 16% with ferritin below 50 µg/L is the most reliable combined indicator of clinically significant iron deficiency, regardless of haemoglobin status.

TSAT above 45% on a fasting morning sample is the key screening signal for hereditary haemochromatosis — and it will be elevated years before ferritin rises to flagrant levels. This makes fasting TSAT the earliest and most sensitive screen for HFE-related iron overload.

Soluble Transferrin Receptor: The Marker Most Panels Miss

Soluble transferrin receptor (sTfR) is shed from cell surfaces — particularly erythroid precursors in the bone marrow — when those cells are starved of iron. The serum sTfR level reflects the aggregate iron demand of all body tissues, independent of inflammation.

This is its crucial clinical advantage: sTfR rises in true iron deficiency and remains normal in anaemia of chronic disease (ACD). Ferritin, by contrast, is elevated by inflammation in ACD, making it unreliable for distinguishing iron deficiency from inflammatory anaemia. sTfR cuts through this ambiguity.

Reference ranges:

| Marker | Reference Range | Notes | |---|---|---| | Soluble transferrin receptor | 0.83–1.76 mg/L (varies by assay) | Elevated in iron deficiency; normal in ACD | | sTfR/log ferritin index | >2 suggests iron deficiency; <1 suggests ACD | Used when both conditions may co-exist |

When to request sTfR specifically:

Suspected iron deficiency in the presence of elevated CRP or known inflammatory disease (where ferritin is unreliable)
Anaemia in patients with rheumatoid arthritis, inflammatory bowel disease, or malignancy — to determine whether iron deficiency is contributing alongside chronic disease
Monitoring iron deficiency in pregnancy, where physiological ferritin dilution occurs
Investigation of unexplained microcytic or normocytic anaemia where the standard panel is equivocal

sTfR is not Medicare-rebatable in all clinical contexts and will typically attract an out-of-pocket cost of $30–$60 when added to a private panel. It is available through major Australian pathology providers including Sullivan Nicolaides, Sonic Healthcare, and Australian Clinical Labs.

Optimal vs Reference Ranges: The Functional Medicine Perspective

The rawmarkers.com framework consistently distinguishes between lab reference ranges (the statistical range of values seen across the tested population) and functional optimal ranges (the ranges associated with best physiological performance based on mechanistic and outcomes data). Nowhere is this distinction more clinically relevant than in iron studies.

| Marker | Lab Reference Range | Functional Optimal | |---|---|---| | Serum iron | 10–30 µmol/L | 14–25 µmol/L (fasting AM) | | Ferritin (men) | 30–500 µg/L | 80–200 µg/L | | Ferritin (women, premenopausal) | 12–200 µg/L | 50–150 µg/L | | Ferritin (women, postmenopausal) | 30–300 µg/L | 70–180 µg/L | | Transferrin | 2.0–3.6 g/L | 2.2–3.2 g/L | | TIBC | 45–72 µmol/L | 50–68 µmol/L | | Transferrin saturation | 16–45% | 20–35% | | sTfR | 0.83–1.76 mg/L | Within reference; elevated signals deficiency |

The most clinically significant gap between reference and optimal is ferritin in premenopausal women. A woman with ferritin of 15 µg/L falls within the lab's reference range at most Australian laboratories but is operating with severely depleted iron stores — a state consistently associated in the literature with fatigue, telogen effluvium (hair shedding), reduced cognitive performance, impaired exercise recovery, and compromised immune function.

Functional medicine clinicians apply stricter lower bounds — typically 50 µg/L for women and 80 µg/L for men — because the research on symptom resolution maps to these thresholds, not to the statistical lower bound of a population that includes widespread subclinical deficiency.

Iron Deficiency Without Anaemia: The Most Commonly Missed Pattern

Iron deficiency without anaemia (IDWA) — sometimes called non-anaemic iron deficiency or pre-anaemic iron deficiency — is the state in which iron stores are depleted enough to cause symptoms and impair function, but haemoglobin has not yet fallen below the diagnostic threshold for anaemia.

It is the most common and most under-treated pattern in iron metabolism.

Why It Happens

The body prioritises haemoglobin synthesis. When iron stores begin to fall, the bone marrow preferentially directs available iron to red blood cell production rather than to other iron-dependent processes — myoglobin synthesis, mitochondrial enzyme function, neurotransmitter synthesis (dopamine and serotonin both require iron-dependent enzymes), and thyroid peroxidase activity. The result is that haemoglobin remains normal while virtually everything else that depends on iron is compromised.

By the time haemoglobin falls, iron stores are severely depleted. IDWA begins well before that point.

The Diagnostic Pattern

| Marker | IDWA Pattern | |---|---| | Ferritin | <50 µg/L (often <30 µg/L) | | Serum iron | Low-normal or low | | Transferrin | Elevated or upper-normal | | TIBC | Elevated | | Transferrin saturation | <20%, often <16% | | Haemoglobin | Normal | | MCV | Normal or low-normal | | sTfR | Elevated — key discriminating marker |

This pattern is most prevalent in premenopausal women with heavy menstrual bleeding, vegetarians and vegans, endurance athletes, pregnant women, and individuals with marginal dietary iron intake combined with absorption-impairing factors (coeliac disease, Helicobacter pylori, long-term proton pump inhibitor use).

Symptoms Associated with IDWA

The clinical presentation of IDWA is often identical to that of iron deficiency anaemia — sometimes more pronounced, because many of the non-haematopoietic consequences of iron deficiency are independent of haemoglobin levels:

Persistent fatigue despite adequate sleep
Hair loss (telogen effluvium — diffuse shedding typically beginning 2–3 months after iron status falls)
Reduced exercise tolerance and slower recovery
Cognitive impairment — poor concentration, word-finding difficulty, brain fog
Restless legs syndrome (iron is required for dopamine synthesis in striatal neurons)
Impaired cold tolerance
Brittle nails and angular cheilitis
Reduced immune function — iron is essential for lymphocyte proliferation and neutrophil oxidative burst

Why It Gets Missed

The standard GP workflow in Australia typically requests FBC alone when fatigue or hair loss is the presenting complaint. If haemoglobin is normal, the result is returned as "normal" without iron studies. Iron studies, when ordered, often show ferritin in the 18–40 µg/L range — within the lab reference range but well below the functional optimal threshold — and the report is again returned as "within normal limits."

The consequence is women, in particular, going years with symptomatic iron deficiency before receiving treatment. The solution is simple: request a full iron panel including ferritin and TSAT whenever iron deficiency is clinically suspected, regardless of FBC result.

Iron Overload and Haemochromatosis Screening

Hereditary haemochromatosis (HH) is one of the most common autosomal recessive genetic conditions in people of Northern European ancestry. In Australia — with its high proportion of Irish, Scottish, English, and Scandinavian heritage — it deserves particular attention.

Australian Prevalence and the HFE Gene

Hereditary haemochromatosis is caused primarily by mutations in the HFE gene, located on chromosome 6. Two mutations account for the overwhelming majority of cases:

C282Y: The primary pathogenic mutation. Homozygous C282Y (inheriting two copies) is the most common cause of hereditary haemochromatosis. Approximately 1 in 200 Australians of Northern European descent carries two copies of this variant — making it one of the most prevalent single-gene disorders in the Australian population.

H63D: A second, milder variant. Compound heterozygosity — one copy of C282Y and one copy of H63D — produces a clinically significant but generally less severe iron overload syndrome, also present in roughly 1 in 200 Australians in its compound heterozygous form.

Homozygous C282Y haemochromatosis has variable penetrance — not all gene carriers develop clinically significant iron overload — but among those who do, the progressive accumulation of iron in the liver, heart, joints, and endocrine organs is predictable and preventable.

How Iron Accumulates

In normal physiology, iron absorption is tightly regulated by hepcidin — a liver-produced peptide hormone that suppresses intestinal iron absorption when stores are adequate. In haemochromatosis, HFE protein dysfunction leads to inappropriately low hepcidin production, and the intestine continues absorbing iron regardless of body stores. Over years to decades, iron accumulates progressively in parenchymal tissues.

The Clinical Consequences of Untreated Overload

Liver: Hepatic fibrosis progressing to cirrhosis and hepatocellular carcinoma — the leading cause of death in untreated haemochromatosis
Pancreas: Diabetes mellitus ("bronze diabetes") from islet cell destruction
Heart: Arrhythmias and dilated cardiomyopathy from myocardial iron deposition
Joints: Chondrocalcinosis and arthropathy, particularly of the second and third metacarpophalangeal joints — a characteristic early clinical sign
Endocrine: Hypogonadism, hypothyroidism, adrenal insufficiency
Skin: Hyperpigmentation from melanin and haemosiderin deposition

The key point is that these consequences are entirely preventable with early detection and treatment. Treatment — regular therapeutic venesection (phlebotomy) to deplete iron stores — is simple, safe, and effective. Individuals diagnosed and treated before significant iron deposition has occurred have a normal life expectancy.

The Screening Pattern

| Marker | Haemochromatosis Screening Pattern | |---|---| | Transferrin saturation | >45% on fasting sample — the earliest and most sensitive screen | | Ferritin | Elevated (often >300 µg/L in women, >400 µg/L in men at presentation) | | Serum iron | Elevated | | TIBC | Low or low-normal (transferrin is not upregulated — iron is abundant) | | Haemoglobin | Normal or elevated |

The key rule: Fasting transferrin saturation above 45% warrants HFE gene testing. Ferritin can be normal in the early stages — TSAT is the earlier signal and should not be ignored even when ferritin is within range.

Medicare and Genetic Testing Access

HFE gene testing (C282Y and H63D mutation analysis) is Medicare-rebatable in Australia when ordered by a GP or specialist in the context of elevated transferrin saturation or a family history of haemochromatosis. First-degree relatives of confirmed C282Y homozygotes should be offered genetic testing regardless of their iron panel results.

B Vitamins, Iron Absorption, and the Methylation Connection

Iron metabolism does not operate in isolation from other nutritional pathways. Two interactions are clinically relevant and underappreciated.

B12, folate, and iron: Vitamin B12 and folate deficiency independently impair red blood cell production (causing macrocytic anaemia), and can coexist with iron deficiency in complex patterns that are diagnostically confusing. In megaloblastic anaemia from B12 or folate deficiency, MCV is elevated (macrocytosis) — but concurrent iron deficiency can normalise MCV, producing a "dimorphic" blood picture that appears misleadingly normal on a routine CBC. For a detailed treatment of homocysteine, B12, and folate status testing, see our article on interpreting homocysteine and B vitamin status.

Vitamin C and non-haem iron absorption: Vitamin C (ascorbic acid) reduces non-haem iron from Fe³⁺ to Fe²⁺, the form absorbed by intestinal enterocytes via the DMT-1 transporter. Consuming 250–500 mg of vitamin C with plant-based iron sources approximately doubles non-haem iron absorption — a particularly important consideration for vegetarians and vegans.

Understanding the bioavailability of different iron forms — from haem iron in red meat (20–30% absorption) to ferrous bisglycinate (moderately high bioavailability) to ferrous sulfate (effective but GI-intolerant for many) — is essential when addressing iron deficiency through supplementation or dietary optimisation.

Iron, Mitochondria, and Energy Metabolism

Iron's role in energy production extends well beyond haemoglobin synthesis and oxygen transport. Iron is an essential component of the mitochondrial electron transport chain — specifically iron-sulphur clusters embedded in Complexes I, II, and III, and cytochrome c (a haem-containing electron carrier). Without adequate iron, mitochondrial ATP generation is impaired at the cellular level, independently of any effect on red blood cells or haemoglobin.

This is why fatigue in iron deficiency often precedes anaemia. Muscle mitochondria, hepatocytes, and neurons all experience impaired mitochondrial energy production before haemoglobin falls — and this explains why restoring haemoglobin alone, without fully restoring ferritin to optimal levels, frequently leaves patients still symptomatic.

Research into metabolic regulators has examined how iron status intersects with mitochondrial biogenesis pathways. MOTS-c, a mitochondria-derived peptide that regulates cellular energy homeostasis, has been studied in the context of exercise metabolism and metabolic resilience — areas where iron status is a foundational variable. Those following the intersection of mitochondrial biology and peptide research can find a summary of the current evidence in MOTS-c mitochondrial research.

Reading the Panel as a System: Diagnostic Patterns

| Pattern | Ferritin | Serum Fe | Transferrin/TIBC | TSAT | sTfR | Hb | |---|---|---|---|---|---|---| | Iron deficiency without anaemia | Low | Low-normal | Elevated | <20% | Elevated | Normal | | Iron deficiency anaemia | Very low | Low | Elevated | <16% | Elevated | Low | | Anaemia of chronic disease | Normal/elevated | Low | Normal/low | Low | Normal | Low | | Combined IDA + ACD | Equivocal | Low | Low/normal | Low | Elevated | Low | | Haemochromatosis | Elevated | Elevated | Low/normal | >45% | Normal | Normal | | Inflammation only (no deficiency) | Elevated | Normal | Low | Normal | Normal | Normal |

The combined IDA + ACD pattern is the most diagnostically challenging. This is precisely where sTfR provides decisive value — it is elevated in true iron deficiency regardless of inflammatory context, and normal in pure ACD. The sTfR/log ferritin index (>2 favours iron deficiency; <1 favours ACD) is a validated discriminator for this scenario.

Testing Access in Australia

Medicare-Rebatable (GP-Referred)

Iron studies — serum iron, ferritin, transferrin, TIBC, and transferrin saturation — are Medicare-rebatable with clinical indication. A GP referral citing symptoms of iron deficiency or risk factors for haemochromatosis will generally support a rebated request.

Soluble transferrin receptor is not universally rebatable and may require specialist ordering or attract a gap payment. HFE gene testing is rebatable when transferrin saturation is elevated or family history is established.

Private Pathology Without a GP Referral

Full iron panels including ferritin, TSAT, and TIBC are available privately in Australia without a referral for approximately $60–$130, depending on the provider and whether sTfR or HFE gene testing is added. Major providers include Sullivan Nicolaides Pathology, Australian Clinical Labs (formerly Healthscope), and Sonic Healthcare subsidiaries including Douglass Hanly Moir (NSW) and Dorevitch (Victoria).

For a comprehensive list of current private testing options in Australia including direct-to-consumer services, pricing, and turnaround times, see the Australian blood testing directory.

Key Takeaways

A full iron panel includes seven distinct markers; most standard "iron studies" requests return only five. Request sTfR specifically when inflammation complicates interpretation.
Serum iron is the least reliable marker in isolation — always interpret alongside TIBC and ferritin.
Ferritin reference ranges, particularly the lower bound for women (as low as 12 µg/L), do not reflect functional sufficiency. Functional optimal is 50–150 µg/L for premenopausal women and 80–200 µg/L for men.
Iron deficiency without anaemia (IDWA) is the most common missed pattern — ferritin below 50 µg/L with normal haemoglobin causes real, measurable symptoms and warrants treatment.
Transferrin saturation above 45% on a fasting morning sample is the primary screening marker for hereditary haemochromatosis — it rises before ferritin becomes markedly elevated.
HFE C282Y homozygosity affects approximately 1 in 200 Australians of Northern European ancestry. HFE gene testing is Medicare-rebatable with elevated TSAT or confirmed family history.
Soluble transferrin receptor is the only iron marker unaffected by inflammation — it is elevated in true iron deficiency and normal in anaemia of chronic disease, making it the key discriminator in patients with concurrent inflammatory conditions.
Iron is essential for mitochondrial electron transport — fatigue in iron deficiency is a cellular energy impairment, not merely a consequence of reduced oxygen-carrying capacity.

This article is for educational purposes only and does not constitute medical advice. Reference ranges vary between Australian pathology laboratories. Consult a qualified medical practitioner for interpretation of your individual results and before commencing iron supplementation or investigation for haemochromatosis.